Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11886-003-0096-y http://scihub22266oqcxt.onion/10.1007/s11886-003-0096-y 12917054!ä!12917054 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Cardiol+Rep 2003 ; 5 (5): 387-94 Nephropedia Template TP {{tp|p=12917054|t=2003. Advances in the acute pharmacologic management of cardiac arrhythmias |pdf=|usr=}}{{12917054}} gab.com Text Advances in the acute pharmacologic management of cardiac arrhythmias JO: Curr Cardiol Rep http://www.kidney.de/pget.php?&tw=1&pmid=12917054 #FOAvip Safe and effective control of rapid ventricular rates in acute-onset atrial fibrillation (AF) can be accomplished with intravenous calcium antagonists, beta-blockers or amiodarone; digoxin is less effective. If pharmacologic cardioversion of AF is desired, single oral doses of propafenone or flecainide are safe and effective in patients without structural heart disease. Intravenous ibulitide is moderately effective in the conversion of persistent AF or atrial flutter, with a small risk of proarrhythmia. In wide QRS complex tachycardia of uncertain origin, adenosine and lidocaine are no longer recommended. Procainamide or amiodarone are the treatment options, but attempts should be made to define the origin of tachycardia. In the treatment of monomorphic ventricular tachycardia, lidocaine is no longer recommended; procainamide or amiodarone are the recommended therapies. In polymorphic ventricular tachycardia with a normal QT interval, beta-blockers are recommended. In shock-refractory ventricular fibrillation, lidocaine, and magnesium are ineffective; intravenous amiodarone should be the treatment of choice. Twit Text FOAVip Advances in the acute pharmacologic management of cardiac arrhythmias ????Curr Cardiol Rep http://www.kidney.de/pget.php?&tw=1&pmid=12917054 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=12917054 #FOAvip English Wikipedia <ref>{{Cite pmid|12917054}}</ref> Advances in the acute pharmacologic management of cardiac arrhythmias #MMPMID12917054 Sarkozy A; Dorian P Curr Cardiol Rep 2003[Sep]; 5 (5): 387-94 PMID12917054show ga Safe and effective control of rapid ventricular rates in acute-onset atrial fibrillation (AF) can be accomplished with intravenous calcium antagonists, beta-blockers or amiodarone; digoxin is less effective. If pharmacologic cardioversion of AF is desired, single oral doses of propafenone or flecainide are safe and effective in patients without structural heart disease. Intravenous ibulitide is moderately effective in the conversion of persistent AF or atrial flutter, with a small risk of proarrhythmia. In wide QRS complex tachycardia of uncertain origin, adenosine and lidocaine are no longer recommended. Procainamide or amiodarone are the treatment options, but attempts should be made to define the origin of tachycardia. In the treatment of monomorphic ventricular tachycardia, lidocaine is no longer recommended; procainamide or amiodarone are the recommended therapies. In polymorphic ventricular tachycardia with a normal QT interval, beta-blockers are recommended. In shock-refractory ventricular fibrillation, lidocaine, and magnesium are ineffective; intravenous amiodarone should be the treatment of choice. |Anti-Arrhythmia Agents/*therapeutic use[MESH] |Arrhythmias, Cardiac/classification/physiopathology/*therapy[MESH] |Disease Management[MESH] |Electric Countershock[MESH] |Electrocardiography[MESH] |Humans[MESH]Advances in the acute pharmacologic management of cardiac arrhythmias (epmc).pdf DeepDyve Pubget Overpricing